Equity Brief · Healthcare2026-05-20
TMO·Healthcare

Thermo Fisher Scientific Inc

I · KI-Analyse

Kurzfassung

Thermo Fisher supplies the tools, chemicals, and services that pharmaceutical companies and research labs need to discover drugs, manufacture medicines, and run diagnostic tests. They operate across four segments: Life Sciences Solutions (research reagents and instruments), Analytical Instruments (lab equipment), Specialty Diagnostics (clinical testing products), and Laboratory Products and Biopharma Services (contract manufacturing and research services for drug companies).

Thermo Fisher Scientific is a $166.4 billion life sciences and laboratory equipment company that provides instruments, reagents, diagnostics, and contract manufacturing services to pharmaceutical, biotech, and research customers worldwide [Yahoo Finance]. The company serves as a critical infrastructure provider for drug development, with recent growth driven by expanding bioprocess services, new laboratory facilities in Sweden, and partnerships to manufacture oncology drugs [Yahoo Finance]. Despite solid fundamentals, the stock has significantly underperformed the market over the past year, rising only 8.3% compared to the S&P 500's 25.2% gain [Yahoo Finance].

Thermo Fisher shows solid profitability with moderate leverage, though return on capital and stock performance lag expectations.

Kurzfassung AI analysisKonfidenz 8/10

Sentinellis-Score

6.8/10

Moderate concerns

Marktkapitalisierung

$166.4B

Umsatz (12 Monate)

$44.6B

II · Aktuelle Nachrichten

Was den Kurs bewegt hat

6 stories · ranked by relevance

  • macro2026-05-20

    Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day

    Yahoo Finance

  • macro2026-05-19

    Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG

    Yahoo Finance

  • macro2026-05-18

    Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading

    Yahoo Finance

  • macro2026-05-18

    Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps

    Simply Wall St

  • macro2026-05-18

    Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden

    Yahoo Finance

  • macro2026-05-18

    Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone

    Simply Wall St

Premium · kostenlos mit jedem Konto

The stock has badly underperformed the market, gaining only 8.3% over the past year while the S&P 500 rose 25.2%, and is down 24.4% year-to-date versus an 8.1% market gain [Yahoo Finance]. This persistent weakness suggests investor concerns about growth trajectory or valuation.

1 von 4 Risiken in diesem Bericht

Risiken

4

Chancen

5

Warnsignale

1

Führung

10

19 weitere Erkenntnisse im vollständigen Bericht — kostenlos mit jedem Konto.

Vollständige Thermo Fisher Scientific Inc-Analyse freischalten

Erstellen Sie ein kostenloses Konto für den vollständigen KI-Bericht mit Quellenangaben im Text.

  • 4 Risiken, 5 Chancen und 1 Warnsignal — jeweils mit Quelle
  • Über 100 Finanzkennzahlen mit Charts und Vergleichen
  • Vollständige Nachrichten-Zusammenfassungen mit Quellenlinks
  • Führungsteam und Vergütung
  • PDF-Export für offline
Alle 10 Erkenntnisse freischalten3 kostenlose Berichte · keine Karte

III · Ähnliche Unternehmen

Das könnte Sie auch interessieren

Same sector · Healthcare or comparable health

Auf Ihre Watchlist setzen?

Read three companies free. Keine Karte.

3 kostenlose Berichte sichern
Thermo Fisher Scientific Inc (TMO) Aktienanalyse in verständlicher Sprache — Sentinellis